Pillar_biosciences_logo
  • Investors
  • Careers
  • Investors
  • Careers
  • Company
    • Our Story
    • Leadership & Advisors
    • Pillar News
    • Distribution Partners
    • Strategic Partnership
  • Technology
  • Products
    • Portfolio Overview
    • IVD Products
    • Solid Tumor Tissue
    • Liquid Biopsy
    • Heme
    • BRCA, HRD, Methylation
    • InheritReveal™ Disease
  • Pharma
  • Resources
    • Resource Overview
    • Webinars and Presentations
    • Publications
    • Posters
  • Contact
  • Company
    • Our Story
    • Leadership & Advisors
    • Pillar News
    • Distribution Partners
    • Strategic Partnership
  • Technology
  • Products
    • Portfolio Overview
    • IVD Products
    • Solid Tumor Tissue
    • Liquid Biopsy
    • Heme
    • BRCA, HRD, Methylation
    • InheritReveal™ Disease
  • Pharma
  • Resources
    • Resource Overview
    • Webinars and Presentations
    • Publications
    • Posters
  • Contact
  • Company
    • Our Story
    • Leadership & Advisors
    • Pillar News
    • Distribution Partners
    • Strategic Partnership
  • Technology
  • Products
    • Portfolio Overview
    • IVD Products
    • Solid Tumor Tissue
    • Liquid Biopsy
    • Heme
    • BRCA, HRD, Methylation
    • Inherited Disease
  • Pharma
  • Resources
    • Resource Overview
    • Webinars and Presentations
    • Publications
    • Posters
  • Contact
  • Careers
  • Investors
  • Company
    • Our Story
    • Leadership & Advisors
    • Pillar News
    • Distribution Partners
    • Strategic Partnership
  • Technology
  • Products
    • Portfolio Overview
    • IVD Products
    • Solid Tumor Tissue
    • Liquid Biopsy
    • Heme
    • BRCA, HRD, Methylation
    • Inherited Disease
  • Pharma
  • Resources
    • Resource Overview
    • Webinars and Presentations
    • Publications
    • Posters
  • Contact
  • Careers
  • Investors

Day: October 24, 2024

Pillar Biosciences Receives CPT® Code for FDA Approved oncoReveal™ CDx Pan-Cancer Solid Tumor IVD Kit

Natick, MA – October 24, 2024 – Pillar Biosciences, Inc., the leader in Decision Medicine™, today announced that they have been granted a unique CPT® Proprietary Laboratory Analyses (PLA) code 0523U from the American Medical Association (AMA) for their FDA approved oncoReveal™ CDx pan-cancer solid tumor in vitro diagnostic (IVD) NGS kit. oncoReveal™ CDx is a NGS […]

Pillar_biosciences_logo
Map-marker-alt Linkedin-in
Privacy Policy
© 2025 Pillar Biosciences. All rights reserved.